

1 **The fading of the mpox outbreak among men who have sex with men: a**
2 **mathematical modelling study**

3

4 **Maria Xiridou, Fuminari Miura, Philippe Adam, Eline Op de Coul, John de Wit, Jacco**
5 **Wallinga**

6

7

SUPPLEMENT

8

9 **The transmission model**

10 We developed a deterministic compartmental model that describes monkeypox virus (MPXV) transmission
11 among men who have sex with men (MSM). A schematic diagram of the model is shown in Figure 1 in the main
12 text. We accounted only for transmission via sexual or intimate contacts among main (steady) and casual sex
13 partners (for brevity, referred to as “sexual contacts”).

14

15 **Sexual partners**

16 MSM were divided into $G = 4$ sexual activity groups, based on the total number of partners with whom they had
17 sexual/intimate contacts. The number of these partners was obtained from data from the first round of the
18 “COVID-19, Sex, and Intimacy Survey”, carried out in the summer of 2020 [1]. The survey was focussed on the
19 impact of the first wave of the pandemic. However, as reference, participants were asked also about their sexual
20 behaviour in the second half of 2019. We used the data of 2019, as representative of sexual activity without the
21 temporal fluctuations caused by the COVID-19 pandemic, but also because participants were asked to report the
22 number of male partners with whom they “had sex/intimacy in the second half of 2019”. Based on this number,
23 we divided the population into four sexual activity groups: very low, fairly low, fairly high, and very high
24 activity. The parameters relating to sexual behaviour of each activity group are shown in Table 2.

25

26 **The course of MPXV infection**

27 Individuals enter the population as susceptible (S_{ui}) when they become sexually active. After infection,
28 individuals are exposed but not infectious (E_{ui}) and later become infectious (I_{ui}). When individuals have
29 symptoms and/or they are tested positive for MPXV infection, they may refrain from physical/sexual contacts or
30 may be in isolation/confinement. We refer to these individuals as “refraining from sexual contacts” (Y_{ui}). We
31 assumed that individuals start refraining from sexual contacts $1/\delta$ days after becoming infectious; infectious
32 cases refraining from sexual contacts can still infect others, with a lower probability of transmission, for
33 instance, because they do not completely refrain from sex contacts. Most of the infectious mpox cases recover
34 after a few weeks and become immune (R_i), but a small fraction of the infectious cases may develop
35 complications and need hospitalization (H_i) or die due to mpox.

36 Individuals born before 1974 were vaccinated in their first year of age against smallpox and that protects against
37 MPXV infection and/or disease. Smallpox vaccination ended in 1974 in the Netherlands. Therefore, we assumed
38 that in 2022 approximately 25% of sexually active MSM is vaccinated (S_{vi}) via the old smallpox vaccination
39 programmes, based on the age distribution of adult men in the Netherlands [2, 3]. We assumed that vaccinated
40 men can still get infected with MPXV (and become exposed, E_{vi}), but at a lower rate than that for unvaccinated
41 individuals. Vaccinated exposed individuals have a lower rate of becoming infectious (I_{vi}), than unvaccinated
42 exposed individuals. Vaccinated infectious cases may refrain from sexual contacts (Y_{vi}). We assumed that
43 vaccination reduces the level of infectivity of vaccinated infectious cases, but the recovery rate, the
44 hospitalization rate, and the MPXV-related death rate are similar for vaccinated and unvaccinated individuals.
45 To account for different levels of protection by the old and the new vaccines, in the model we included
46 individuals vaccinated in 2022 separately from those who had been vaccinated in the past (before 1974). The
47 respective compartments in the model are denoted with $S_{pi}, E_{pi}, I_{pi}, Y_{pi}$ (uninfected, exposed, infectious not
48 refraining from sexual contacts, infectious refraining from sexual contacts, respectively) with the subscript
49 p denoting those vaccinated in 2022 by means of pre-exposure or post-exposure prophylaxis. Susceptible
50 individuals (unvaccinated or vaccinated in the past) may be vaccinated in 2022 at a rate φ_{1i} . Exposed individuals
51 (unvaccinated or vaccinated in the past) may be vaccinated in 2022 at a rate φ_{2i} . The vaccination rates φ_{1i} and
52 φ_{2i} depend on the activity group i . We assumed that the protection of the new vaccine (against infection and
53 disease) is higher than that from the old vaccine (Table 1). Both vaccine protections were modelled as a
54 proportional reduction in the transmission rate.

55 Hospitalized cases may die due to mpox or recover and become immune (R_i). All MSM entering the sexually
56 active population in 2022 are unvaccinated and susceptible to MPXV.

57

58 **Model equations**

59 The model is described by the system of ordinary differential equations shown below. The subscript u denotes
60 unvaccinated individuals, v denotes individuals vaccinated in the past (with the old vaccine), p denotes
61 individuals vaccinated in 2022 (with the new vaccine), and $i = 1, 2, \dots, G$ denotes the i -th sexual activity group.

62 Equations for unvaccinated individuals:

$$63 \quad \frac{dS_{ui}}{dt} = -(\lambda_i + \varphi_{1i} + \mu)S_{ui} + \mu N_i$$

$$64 \quad \frac{dE_{ui}}{dt} = \lambda_i S_{ui} - (\varphi_{2i} + \theta + \mu) E_{ui}$$

$$65 \quad \frac{dI_{ui}}{dt} = \theta E_{ui} - (\delta + \zeta + \mu + \mu_d) I_{ui}$$

$$66 \quad \frac{dY_{ui}}{dt} = \delta I_{ui} - (\gamma + \zeta + \mu + \mu_d) Y_{ui}$$

67 Equations for individuals vaccinated in the past:

$$68 \quad \frac{dS_{vi}}{dt} = -(\sigma_1 \lambda_i + \varphi_{1i} + \mu) S_{vi}$$

$$69 \quad \frac{dE_{vi}}{dt} = \sigma_1 \lambda_i S_{vi} - (\theta + \varphi_{2i} + \mu) E_{vi}$$

$$70 \quad \frac{dI_{vi}}{dt} = \sigma_1 \theta E_{vi} - (\delta + \zeta + \mu + \mu_d) I_{vi}$$

$$71 \quad \frac{dY_{vi}}{dt} = \delta I_{vi} - (\gamma + \zeta + \mu + \mu_d) Y_{vi}$$

72 Equations for individuals vaccinated in 2022:

$$73 \quad \frac{dS_{pi}}{dt} = \varphi_{1i}(S_{ui} + S_{vi}) - (\sigma_2 \lambda_i + \mu) S_{pi}$$

$$74 \quad \frac{dE_{pi}}{dt} = \sigma_2 \lambda_i S_{pi} + \varphi_{2i}(E_{ui} + E_{vi}) - (\theta + \mu) E_{pi}$$

$$75 \quad \frac{dI_{pi}}{dt} = \sigma_2 \theta E_{pi} - (\delta + \mu) I_{pi}$$

$$76 \quad \frac{dY_{pi}}{dt} = \delta I_{pi} - (\gamma + \mu) Y_{pi}$$

77 Equations for recovered/immune and hospitalized individuals:

$$78 \quad \frac{dR_i}{dt} = \gamma(Y_{ui} + Y_{vi} + Y_{pi} + H_i) + (1 - \sigma_1)\theta E_{vi} + (1 - \sigma_2)\theta E_{pi} - \mu R_i$$

$$79 \quad \frac{dH_i}{dt} = \zeta(I_{ui} + I_{vi} + Y_{ui} + Y_{vi}) - (\gamma + \mu + \mu_d) H_i$$

80 The parameters and variables in these equations are explained in the following sections and in Tables 1-3.

81 **Transmission rate**

82 The rate at which MSM in activity group i get infected with MPXV is $\lambda_i = \lambda_{mi} + \lambda_{ci}$, where λ_{mi} and λ_{ci} denote
 83 the rates of getting infected by main and casual partners, respectively:

- 84 • The rate of getting infected by main regular partners:

85
$$\lambda_{mi} = q_i \sum_{k=u,v,p} \sum_{j=1}^4 m_{Mij} [1 - (1 - \beta_{sk})^{u_{ij}}] \frac{I_{kj} + wY_{kj}}{N_j}$$

86

- 87 • The rate of getting infected by casual partners:

88
$$\lambda_{ci} = \alpha_{ci} \sum_{k=u,v,p} \sum_{j=1}^4 \beta_{sk} m_{Cij} \frac{I_{kj} + wY_{kj}}{N_j}$$

89 In these equations, the following notation is used:

- 90 • q_i is the fraction of MSM of activity group i with a main regular partner.
- 91 • u_{ij} is the frequency of sex contacts between main sexual partners of activity groups i, j , calculated as $u_{ij} =$
 92 $(u_i + u_j)/2$, from the contact frequency u_i and u_j of sexual activity groups i and j , respectively.
- 93 • β_{sk} is the probability of transmission of MPXV per sexual/intimate contact from an infectious individual
 94 who is unvaccinated ($k = u$), vaccinated in the past ($k = v$), or vaccinated in 2022 ($k = p$), with $\beta_{su} = \beta_s$,
 95 $\beta_{sv} = v_1\beta_s$, $\beta_{sp} = v_2\beta_s$. The probability β_s of transmission per sexual contact with an unvaccinated
 96 individual is reduced by v_1 for those who were vaccinated in the past and by v_2 for those vaccinated in
 97 2022.
- 98 • w is a factor reducing the transmission potential of an infectious individual practicing sexual abstinence
 99 compared to infectious individuals not in abstinence.
- 100 • α_{ci} is the number of casual sex contacts per day for men in activity group i .
- 101 • N_j is the total size of activity group j and $N = \sum_{j=1}^G N_j$ is the total size of the MSM population.
- 102 • m_{Mij} and m_{Cij} are parameters that define the level of mixing between sexual activity groups i, j , when
 103 forming main and casual partnerships, respectively. These are defined by the equations:

104
$$m_{Mij} = \varepsilon_M \delta_{ij} + (1 - \varepsilon_M) \frac{\alpha_{Mj} N_j}{\sum_{v=1}^G \alpha_{Mv} N_v} \quad \text{and} \quad m_{cij} = \varepsilon_c \delta_{ij} + (1 - \varepsilon_c) \frac{\alpha_{cj} N_j}{\sum_{v=1}^G \alpha_{cv} N_v},$$

105 where δ_{ij} is the Kronecker delta (being equal to 1, if $i = j$; and equal to 0, otherwise) and the parameters
 106 $\varepsilon_s, \varepsilon_c$ determine the level of assortativeness in mixing of activity groups when forming main and casual
 107 partnerships, respectively (if $\varepsilon_i = 1$, then mixing is assortative; if $\varepsilon_i = 0$, then mixing is proportionate).

108

109 **The size of the MSM population**

110 Estimates of the size of the MSM population vary from 111,072 [4] to 392,000 [5]. The variation depends
 111 mostly on the ages included in the estimate (for instance, from 15 or 17 years old; up to 65 or 69 years old) and
 112 the definition of MSM (men who had sex with men in the previous six/twelve months; or ever having sex with
 113 men; or identifying themselves as homosexual/bisexual). Based on the size of the male population [2] and
 114 prevalence estimates of same-sex behaviour [5], we assumed that the number of MSM in 2022 was around
 115 250,000. Due to uncertainty about this estimate, we repeated the analyses with 200,000 MSM and 300,000
 116 MSM.

117

118 **Adaptations that may have occurred in the first three months of the outbreak**

119 By ordering diagnosed mpox cases according to date of symptom onset, the peak was between 6 and 10 July
 120 2022. The first diagnosis of mpox was on 20 May 2022. By the beginning of June, the number of diagnoses was
 121 increasing and there were messages about mpox in the news, social media, and MSM websites [6-9]. This has
 122 probably enhanced awareness among MSM and health care practitioners, enabling earlier recognition of mpox
 123 symptoms, even during the prodromal phase with systemic symptoms like fever, fatigue, and ache. In an online
 124 survey carried out in August 2022, most MSM responded correctly to questions about symptomatology and
 125 routes of transmission of mpox and reported to be willing to refrain from close physical and sexual contacts if
 126 they were infected with MPXV [10]. As the severity of the outbreak was increasing, MSM were possibly more
 127 willing to refrain from sexual/intimate contacts when they suspected or were diagnosed with MPXV infection,
 128 thus reducing the time they were infectious and not yet refraining from sexual contacts. The spread of
 129 information about mpox and the severity of the outbreak may have also influenced the sexual behaviour of
 130 MSM. In the same survey, more than half of the participants reported a reduction in their sexual activity due to
 131 the mpox outbreak [10]. Furthermore, sex venues and parties reported low numbers of visitors in July 2022 [11],

132 with the reduction reaching its maximum at the end of July, when some club owners observed up to 30% less
133 visitors than what was expected (P. Zantkuijl, personal communication). This points to a decline in sexual
134 activity of men visiting these accommodations.

135 Therefore, in this study, we examined two possible adaptations: (a) MSM may start refraining from sexual
136 contacts earlier during the infectious period, thus resulting in shorter infectious period while not refraining from
137 sexual contacts and (b) a reduction in the number of casual partners. The level and the timing of the adaptations
138 was obtained from the fitting process. We examined two scenarios with adaptations either (a) at one time point
139 T_2 in the period 5-15 July 2022 or (b) at two time points T_1 in the period 17-27 June 2022 and T_2 in the period 5-
140 15 July 2022. These time periods were close to messages placed on ManTotMan socials and the announcement
141 of the Dutch government on 7 July 2022 to start with the monkeypox vaccination programme.

142 We included a reduction D_{4j} in the number of casual partners of men in the very high sexual activity group, D_{3j}
143 for men in the fairly high sexual activity group, and a reduction D_{2j} for men in the very low and fairly low
144 sexual activity groups. The reduction D_{ij} occurred on day $T_j = T_1$ or $T_j = T_2$. The six values D_{ij} ($i = 2,3,4$ and
145 $j = 1,2$) were sampled from the same range (0-30% reduction), since we are uncertain about the occurrence of
146 the decline. Similarly, we sampled three values for the duration of the infectious period before refraining from
147 sexual contacts: one for the duration in the beginning of the outbreak, a second value for the period between T_1
148 and T_2 , and a third value for the period after T_2 . All three values were sampled from the same range (2-8 days)
149 since we were uncertain whether an adaptation in this duration occurred and when.

150

151 **Model fitting**

152 The model was fitted to data on the number of diagnosed mpox cases using a Bayesian approach. Parameters
153 relating to sexual behaviour were estimated from data or obtained from the literature (Table 2), except from: (a)
154 the two parameters for assortativeness in sexual mixing and (b) the number of casual partners of the group with a
155 very high sexual activity level. These were included as uncertain parameters, due to lack of reliable data and
156 because the model results were very sensitive to these parameters (based on our preliminary analyses). Further,
157 most of the parameters relating to mpox were uncertain (Table 1) and were obtained via the fitting process.

158

159

160 The uncertain parameters were divided into two groups:

- 161 1. Parameters relating to behavioural adaptations that occurred in June/July 2022 (Table 3): adaptation in the
162 number of casual partners; adaptation in the number of days that an individual is infectious and not in
163 abstinence; and two parameters for the timing of these adaptations.
- 164 2. Main parameters (Table 1): all the other parameters, except those relating to the adaptations that occurred in
165 June/July 2022.

166 The fitting process was carried out in two steps:

- 167 1. In the first step, we fitted the model to the numbers of daily mpox cases registered in the national database
168 of notifiable infectious diseases of the Netherlands until 17 June or until 5 July 2022. We defined uniform
169 prior distributions for the uncertain parameters (Tables 1). Using Latin Hypercube Sampling [12], we
170 sampled 10,000 combinations of values from the prior distributions and repeated the model calculations
171 with each parameter combination. From the model, we calculated the daily numbers of mpox cases with
172 each parameter combination. We calculated the Poisson likelihood of the above numbers, thus obtaining the
173 posterior distributions of the uncertain parameters (except those relating to the behavioural adaptations in
174 June/July 2022), reflecting the situation in the beginning of the outbreak.
- 175 2. In the second step, we used the posterior distributions obtained from the first step of the fitting process and
176 fitted the model to data from 17 June or 5 July 2022 until 25 July 2022. The modelled mpox cases were
177 compared with the respective data with date of symptom onset in this time interval. We calculated their
178 Poisson likelihood and obtained the posterior distributions of the uncertain parameters relating to
179 behavioural adaptations that occurred in June/July 2022.

180


181 **Data sources**

182 The following data sources were used in this study.

183 *National surveillance system for notifiable diseases (OSIRIS)*: Individuals seeking mpox testing or presenting
184 with symptoms suggestive of mpox to general practitioners or health centres were referred and notified to the
185 regional public health service for mpox diagnostics [9]. Notification of confirmed mpox cases from regional
186 public health services to the National Institute of Public Health and the Environment was accompanied by a
187 questionnaire with demographical, clinical, and epidemiological information of cases. The numbers of confirmed


188 mpox cases according to date of symptom onset were extracted from this database. These numbers were
189 continuously updated during the outbreak and were available online on <https://www.rivm.nl/mpox-apenpokken>.
190 *COVID-19, Sex, and Intimacy Survey*: This is a repeated cross-sectional self-report survey. The first round of
191 data collection was carried out from the end of July 2020 to the beginning of September 2020 [13, 14].
192 Participants were recruited via social media advertisement on Facebook and Instagram. People were eligible to
193 participate if they: lived in the Netherlands, were 18 years or older, identified as male and ever had sex with a
194 man. All participants provided informed consent and received no compensation. Only responses from eligible
195 participants who fully completed the questionnaire were used for the analyses presented here. The aim of the
196 survey was to investigate the impact of the COVID-19 pandemic on sexual behaviour. Therefore, respondents
197 were asked to report on their sexual behaviour during the first half of 2020 and, as reference, their sexual
198 behaviour during the last six months of 2019. In the present study, we used data only from the responses for the
199 period July-December 2019. For these questions, 5,683 participants reported their sexual behaviour.

200




201

202 **Figure S1.** The cumulative number of mpoX cases among MSM in the Netherlands from 27 April to 25 July
 203 2022. Cases are shown according to date of symptom onset (on horizontal axes). Solid black line shows data
 204 from 27 April to 25 July 2022, from the national database of notifiable infectious diseases of the Netherlands.
 205 Orange box-plots show the medians and interquartile ranges obtained from the model in a population of 250,000
 206 MSM (a) without behavioural adaptations; (b) with behavioural adaptations only in July 2022; (c) with
 207 behavioural adaptations in June and in July 2022. In (b)-(c), the vertical grey lines show the medians (solid line)
 208 and the 95% credible intervals (dashed lines) of the time point at which the adaptations occurred, as obtained
 209 from the model fitting.



211 **Figure S2.** The daily number of mpox cases among MSM in the Netherlands from 27 April to 25 July 2022.
 212 Black bullets show data from the national database of notifiable diseases of the Netherlands; the other lines were
 213 calculated from the model. Mpox cases are shown according to date of symptom onset. Left panels: box-plots of
 214 daily number of mpox cases in the overall MSM population. Right panels: median daily number of mpox cases
 215 in the overall MSM population (black line), in the groups with high sexual activity level (red lines), and in the
 216 groups with low sexual activity level (blue lines). (a), (b): without behavioural adaptations; (c), (d): with
 217 behavioural adaptations in July 2022. Vertical grey lines show median (solid line) and 95% credible interval
 218 (dashed lines) of the day at which the behavioural adaptations occurred, as obtained from the model fitting.
 219 Model results were calculated in a population of 200,000 MSM.



221

222 **Figure S3.** The daily number of mpox cases among MSM in the Netherlands from 27 April to 25 July 2022.

223 Black bullets show data from the national database of notifiable diseases of the Netherlands; the other lines were

224 calculated from the model. Mpox cases are shown according to date of symptom onset. Left panels: box-plots of

225 daily number of mpox cases in the overall MSM population. Right panels: median daily number of mpox cases


226 in the overall MSM population (black line), in the groups with high sexual activity level (red lines), and in the

227 groups with low sexual activity level (blue lines). (a), (b): without behavioural adaptations; (c), (d): with

228 behavioural adaptations in July 2022. Vertical grey lines show median (solid line) and 95% credible interval

229 (dashed lines) of the day at which the behavioural adaptations occurred, as obtained from the model fitting.


230 Model results were calculated in a population of 300,000 MSM.



231

232 **Figure S4.** Sensitivity analyses for the percentage of the population being vaccinated in the past (before 1974),
 233 via the old smallpox vaccination programme. Two scenarios are shown, with behavioural adaptations in July
 234 2022, in a population of 250,000 MSM, of whom 25% in total had been vaccinated in the past. Top panels: the
 235 percentage vaccinated in the past was the highest in the group with the highest level of sexual activity: 23%,
 236 25%, 30%, 40% vaccinated in the group with very low, fairly low, fairly high, or very high level of sexual
 237 activity, respectively. Bottom panels: the percentage vaccinated in the past was the highest in the group with the
 238 lowest level of sexual activity: 29%, 25%, 15%, 10% vaccinated in the group with very low, fairly low, fairly
 239 high, or very high level of sexual activity, respectively. Numbers shown are the daily numbers of mpox cases
 240 among MSM in the Netherlands from 27 April to 25 July 2022, from the data (black bullets) and from the model
 241 (orange box plots and lines) – the plots are as explained in Figure S3.

242



243

244 **Figure S5.** The daily number of mpox cases among MSM in the Netherlands from 27 April to 31 December
 245 2022, in the scenario without behavioural adaptations. Black bullets show data from the national database of
 246 notifiable diseases of the Netherlands, as shown in Figure 4a in the main text. The lines were calculated from the
 247 model. Mpox cases are shown according to date of symptom onset. Black solid line: median; black dashed line:
 248 maximum; red lines: interquartile range; blue lines, 95% credible interval; cyan line, upper 5th percentile; green
 249 line, upper 10th percentile. Vertical grey lines show the last day of each calendar month. Model results were
 250 calculated in a population of 250,000 MSM.

251
252
253

Table S1. Posterior distributions of uncertain model parameters obtained from the fitting process for the two scenarios with adaptations in behaviour of MSM only in July 2022 or in June and July 2022. Results shown are the medians and 95% credible intervals, in a population of 250,000 MSM.

	Adaptations only in July 2022			Adaptations in June & July 2022		
	Median	95% range		Median	95% range	
Latent period, days ($1/\theta$)	5.67	5.03	6.97	5.80	5.10	7.81
Infectious period ($1/\gamma + 1/\delta$)	16.75	14.27	24.07	18.41	14.26	24.46
Transmission probability per sex act	0.48	0.39	0.81	0.48	0.39	0.67
Number casual partners per day, very-high activity group	0.89	0.73	1.00	0.90	0.73	1.00
Factor reducing transmission when in abstinence (w)	19%	15%	37%	22%	16%	46%
Assortativeness mixing with main partners (ϵ_M)	0.72	0.13	0.88	0.69	0.12	0.85
Assortativeness mixing with casual partners (ϵ_C)	0.87	0.20	0.90	0.84	0.48	0.90
Vaccination rate before 25 July 2022	0.04%	0.03%	0.05%	0.04%	0.03%	0.05%
Efficacy old vaccine ($v_1 = \sigma_1$)	56%	52%	65%	58%	50%	63%
Efficacy new vaccine ($v_2 = \sigma_2$)	85%	80%	90%	85%	80%	89%
Hospitalization rate, ζ	1%	1%	2%	2%	1%	2%
Days infectious not refraining from sex, before T_1	6.05	4.45	7.80	6.89	3.74	7.78
Days infectious not refraining from sex, between T_1 and T_2	As before T_1			5.60	2.94	7.83
Days infectious not refraining from sex, after T_2	2.55	2.00	4.31	2.44	2.02	4.87
Date of adaptations in June, T_1	Not applicable			21-6-2022	17-6-2022	26-6-2022
Date of adaptations in July, T_2	7-7-2022	5-7-2022	11-7-2022	10-7-2022	5-7-2022	14-7-2022
% reduction casual partners, low activity groups, after T_2	13%	1%	28%	13%	0%	28%
% reduction casual partners, fairly-high activity group, after T_2	15%	1%	29%	18%	3%	29%
% reduction casual partners, very-high activity group, after T_2	24%	1%	30%	22%	4%	30%
% reduction casual partners, low activity groups, between T_1 and T_2	Not applicable			17%	2%	29%
% reduction casual partners, fairly-high activity group, between T_1 and T_2				16%	1%	29%
% reduction casual partners, very-high activity group, between T_1 and T_2				18%	1%	29%

254

255 **Table S2.** Posterior distributions of uncertain model parameters obtained from the fitting process for the scenario with adaptations in behaviour of MSM only in July 2022.
 256 Results shown are the medians and 95% credible intervals, in a population of 200,000 or 300,000 MSM.

257

	200,000 MSM			300,000 MSM		
	Median	95% range		Median	95% range	
Latent period, days ($1/\theta$)	5.51	5.04	7.77	5.67	5.04	7.74
Infectious period ($1/\gamma + 1/\delta$)	18.41	14.51	26.75	15.54	14.22	25.88
Transmission probability per sex act	0.50	0.39	0.66	0.49	0.45	0.81
Number casual partners per day, very-high activity group	0.91	0.72	1.00	0.90	0.72	0.98
Factor reducing transmission when in abstinence (w)	23%	17%	60%	20%	15%	30%
Assortativeness mixing with main partners (ϵ_M)	0.72	0.31	0.87	0.75	0.14	0.88
Assortativeness mixing with casual partners (ϵ_C)	0.85	0.66	0.89	0.75	0.20	0.89
Vaccination rate before 25 July 2022	0.04%	0.03%	0.05%	0.04%	0.03%	0.05%
Efficacy old vaccine ($v_1 = \sigma_1$)	57%	50%	65%	56%	51%	65%
Efficacy new vaccine ($v_2 = \sigma_2$)	85%	80%	90%	82%	80%	90%
Hospitalization rate, ζ	2%	1%	2%	2%	1%	2%
Days infectious not refraining from sex, before T_2	6.20	2.73	7.87	5.82	4.62	7.98
Days infectious not refraining from sex, after T_2	2.80	2.02	6.60	2.24	2.02	2.80
Date of adaptations in July, T_2	8-7-2022	5-7-2022	14-7-2022	6-7-2022	5-7-2022	9-7-2022
% reduction casual partners, low activity groups, after T_2	13%	0%	29%	11%	0%	28%
% reduction casual partners, fairly-high activity group, after T_2	17%	1%	29%	14%	1%	29%
% reduction casual partners, very-high activity group, after T_2	22%	2%	29%	22%	2%	29%

258

259 **Table S3.** Sensitivity analysis for the percentage of MSM vaccinated in the past via the old smallpox vaccination programme. Posterior distributions of uncertain model
 260 parameters obtained from the fitting process for the scenario with adaptations in behaviour of MSM only in July 2022. Results shown are the medians and 95% credible
 261 intervals, in a population of 250,000 MSM.

262

	Higher % vaccinated in group with highest level of sexual activity*			Higher % vaccinated in group with lowest level of sexual activity**		
	Median	95% range		Median	95% range	
Latent period, days ($1/\theta$)	5.67	5.11	6.76	5.53	5.02	6.92
Infectious period ($1/\gamma + 1/\delta$)	16.08	14.48	26.54	17.61	14.48	26.61
Transmission probability per sex act	0.60	0.47	0.80	0.42	0.32	0.68
Number casual partners per day, very-high activity group	0.90	0.73	0.98	0.85	0.73	0.99
Factor reducing transmission when in abstinence (w)	21%	16%	41%	20%	16%	37%
Assortativeness mixing with main partners (ϵ_M)	0.75	0.21	0.90	0.67	0.10	0.88
Assortativeness mixing with casual partners (ϵ_C)	0.79	0.27	0.90	0.82	0.33	0.90
Vaccination rate before 25 July 2022	0.04%	0.03%	0.05%	0.04%	0.03%	0.05%
Efficacy old vaccine ($v_1 = \sigma_1$)	59%	50%	65%	55%	51%	64%
Efficacy new vaccine ($v_2 = \sigma_2$)	84%	81%	89%	82%	80%	90%
Hospitalization rate, ζ	2%	1%	2%	2%	1%	2%
Days infectious not refraining from sex, before T_2	6.31	4.25	7.82	6.68	3.80	7.98
Days infectious not refraining from sex, after T_2	2.41	2.08	4.36	2.36	2.01	4.24
Date of adaptations in July, T_2	6-7-2022	5-7-2022	11-7-2022	6-7-2022	5-7-2022	10-7-2022
% reduction casual partners, low activity groups, after T_2	16%	2%	29%	12%	1%	29%
% reduction casual partners, fairly-high activity group, after T_2	20%	1%	30%	16%	3%	28%
% reduction casual partners, very-high activity group, after T_2	23%	4%	29%	26%	5%	30%

263

264 * The percentage vaccinated in the past in the group with very low, fairly low, fairly high, or very high level of sexual activity was 23%, 25%, 30%, 40%, respectively. This
 265 results in a total of 25% being vaccinated in the total MSM population.

266 ** The percentage vaccinated in the past in the group with very low, fairly low, fairly high, or very high level of sexual activity was 29%, 25%, 15%, 10%, respectively. This
 267 results in a total of 25% being vaccinated in the total MSM population.

268 **References**

- 269 1. Xiridou M, Heijne J, Adam P, Op de Coul E, Matser A, de Wit J, et al. How the Disruption in
270 Sexually Transmitted Infection Care Due to the COVID-19 Pandemic Could Lead to Increased
271 Sexually Transmitted Infection Transmission Among Men Who Have Sex With Men in The
272 Netherlands: A Mathematical Modeling Study. *Sex Transm Dis.* 2022;49(2):145-53. doi:
273 10.1097/olq.0000000000001551. PubMed PMID: 34475357.
- 274 2. Statistics Netherlands. The Netherlands in figures 2022 [3 July 2022]. Available from:
275 <https://opendata.cbs.nl/#/CBS/en>.
- 276 3. National Institute of Public Health and the Environment (RIVM). Online National System of
277 Registration of Infectious Diseases (OSIRIS): National Institute of Public Health and the Environment
278 (RIVM); 2021 [Accessed: 13 December 2021]. Available from: [https://www.rivm.nl/sniv/handleiding-](https://www.rivm.nl/sniv/handleiding-osiris)
279 [osiris](https://www.rivm.nl/sniv/handleiding-osiris).
- 280 4. Marcus U, Hickson F, Weatherburn P, Schmidt AJ. Estimating the size of the MSM
281 populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD)
282 between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and
283 surveillance-reported HIV diagnoses among MSM in 2009. *BMC Public Health.* 2013;13:919. Epub
284 2013/10/04. doi: 10.1186/1471-2458-13-919. PubMed PMID: 24088198; PubMed Central PMCID:
285 PMC3850943.
- 286 5. Rutgers NISSO Group. Sexual health in the Netherlands. Delft: Eburon; 2006.
- 287 6. Man Tot Man. Do this if you have monkeypox. [Accessed: 24 January 2023]. Available from:
288 <https://www.mantotman.nl/en/do-this-if-you-have-monkeypox>.
- 289 7. Soa Aids Nederland. Uit de praktijk: 2 plekjes op de eikel, dat is toch geen monkeypox?
290 Published online: 30 June 2022. Accessed 15 November 2022. Available from:
291 [https://www.soa aids.nl/nl/professionals/themas/seksoa-magazine/uit-praktijk-2-plekjes-op-eikel-dat-](https://www.soa aids.nl/nl/professionals/themas/seksoa-magazine/uit-praktijk-2-plekjes-op-eikel-dat-is-toch-geen-monkeypox)
292 [is-toch-geen-monkeypox](https://www.soa aids.nl/nl/professionals/themas/seksoa-magazine/uit-praktijk-2-plekjes-op-eikel-dat-is-toch-geen-monkeypox).

- 293 8. NOS Nieuws. In the Netherlands 167 persons diagnosed with monkeypox by now (original
294 title: "In Nederland nu bij 167 mensen apenpokkenbesmetting vastgesteld"): NOS; 2022 [Accessed 15
295 November 2022]. Available from: [https://nos.nl/artikel/2433610-in-nederland-nu-bij-167-mensen-
apenpokkenbesmetting-vastgesteld](https://nos.nl/artikel/2433610-in-nederland-nu-bij-167-mensen-
296 apenpokkenbesmetting-vastgesteld).
- 297 9. van Ewijk C, Miura F, van Rijckevorsel G, de Vries H, Welkers M, van den Berg O, et al.
298 Monkeypox outbreak in the Netherlands in 2022: public health response, epidemiological and clinical
299 characteristics of the first 1000 cases and protection of the first-generation smallpox vaccine.
300 Eurosurveillance. 2023;28:2200772 Epub 23/3/2023.
- 301 10. Adam PCG, Op de Coul ELM, Bos H, Zantkuijl P, Zuilhof W, Xiridou M, et al. Monkeypox-
302 related changes in behaviour among MSM in the Netherlands and their impact on the monkeypox
303 outbreak: using behavioural research and theorising to inform the monkeypox response. Utrecht
304 University and Institute for Prevention and Social Research, Utrecht, the Netherlands, 2022.
- 305 11. Soa Aids Nederland. Samenwerking zorg en horeca onmisbaar in aanpak monkeypox-uitbraak
306 [Accessed 15 November 2022]. Available from: [https://www.soaaid.nl/nl/professionals/
actueel/nieuwsbericht/samenwerking-zorg-horeca-onmisbaar-in-aanpak-monkeypox-uitbraak](https://www.soaaid.nl/nl/professionals/
307 actueel/nieuwsbericht/samenwerking-zorg-horeca-onmisbaar-in-aanpak-monkeypox-uitbraak).
- 308 12. McKay KDB, R.J.; Conover, W.J. A comparison of three methods for selecting values of input
309 variable in the analysis of output from a computer code. Technometrics 1979;21:239-45.
- 310 13. Adam P, Op de Coul E, Zuilhof W, Zantkuijl P, den Daas C, de Wit J. Changes in MSM's
311 sexual activity, PrEP use, and access to HIV/STI testing during and after the first Dutch COVID-19
312 lockdown. Sexually Transmitted Infections. 2021;97(Supplement 1):A26.
- 313 14. Adam PCG, Zuilhof W, Den Daas C, Op de Coul E, Zantkuijl P, Paolucci J, et al. Reduction
314 in the magnitude of COVID-19-associated changes in sexual activity and disruption in HIV/STI
315 testing or PrEP use among MSM responding to the 2nd COVID-19, sex and intimacy survey.
316 National Conference on HIV; 23 November 2021; Virtual2021.
- 317